Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma Inc.

Immix Biopharma, Inc. (($IMMX)) announced an update on their ongoing clinical study. Immix Biopharma, Inc. is collaborating on a Phase 1b/2 clinica...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMMX	$4.33	+7.71%	381.98K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMMX	$4.33	+7.7%	381.98K
3
4
5
6

IMMX

IMMX

Latest News for IMMX

Get Immix Biopharma Inc. Data in Excel

Get Immix Biopharma Inc. Data in Excel